Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks.
about
Outcome after reduced chemotherapy for intermediate-risk neuroblastomaRisk definition and management strategies in retinoblastoma: current perspectivesInhibition of human topoisomerase II in vitro by bioactive benzene metabolitesThe mixed lineage leukemia fusion partner AF9 binds specific isoforms of the BCL-6 corepressorSecondary acute myeloid leukemia after successful treatment for osteosarcoma.Leukemias related to treatment with DNA topoisomerase II inhibitors.Cancer incidence among adolescents and young adults in urban Shanghai, 1973-2005Etoposide quinone is a redox-dependent topoisomerase II poisonChromosomal translocations involving the MLL gene: molecular mechanisms.Molecular pathogenesis of secondary acute promyelocytic leukemiaTherapy-related leukemia and myelodysplasia: evolving concepts of pathogenesis and treatment.Acute myeloid leukemia following etoposide therapy for EBV-associated hemophagocytic lymphohistiocytosis: a case report and a brief review of the literature.Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitorProspective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndromeTopoisomerase II and leukemia.Cytogenetic instability in childhood acute lymphoblastic leukemia survivors.Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma.Nucleolytic cleavage of the mixed lineage leukemia breakpoint cluster region during apoptosis.Haematologic Malignancy Secondary to the Treatment of Lymphoma.Therapy-related Acute Myeloid Leukemia after the Long-term Administration of Low-dose Etoposide for Chronic-type Adult T-cell Leukemia-lymphoma: A Case Report and Literature Review.Etoposide quinone is a covalent poison of human topoisomerase IIβ.Morbidity and mortality after treatment of Ewing sarcoma: A single-institution experience.Leukaemogenesis, gene interplay, and the role of the haemopoietic environment.Cytogenetics of leukemia.Second malignant neoplasms following the treatment of brain tumors in children.High-dose chemotherapy followed by stem cell rescue for high-risk germ cell tumors: the Stanford experience.Etoposide as a single agent in the treatment of mycosis fungoides: A retrospective analysis.Risk of secondary leukemia after treatment with etoposide (VP-16) for Langerhans' cell histiocytosis in Italian and Austrian-German populations.Apurinic sites are position-specific topoisomerase II poisons.Comparison between intravenous chemotherapy and intra-arterial chemotherapy for retinoblastoma: a meta-analysis.Analysis of Vgamma/Jbeta trans-rearrangements in paediatric patients undergoing chemotherapyIndeterminate cell histiocytosis in association with later occurrence of acute myeloblastic leukaemia
P2860
Q24633964-A835C720-48C6-4016-A3D0-6DC49F5EA267Q26849675-1ED88524-DDB5-4798-9538-06351FADCEF3Q28379582-81A27477-9A16-4DB7-A31A-F83E114C991AQ28591742-9255C3B0-4F91-4604-9147-8B2973F0A131Q33392211-97538A85-0876-430E-B3C3-98A8FBE9A680Q34243503-5A66F1F2-453D-4CDC-808E-BBCD6695D618Q34374429-A2E10EF3-7FF4-4731-9189-C6AFDED76154Q35058862-48A75EB7-56BE-4D65-B338-AA9061E534ADQ35128590-1C879AE2-D358-4C8F-8BD0-1A91BDA6A760Q35560260-82F4389E-E539-4263-9287-FC848F2572E9Q35809447-D4820478-EB57-46E6-A94A-50E387ADD903Q36090310-C31FE1B8-D4DD-42D0-8CA4-1579376C54EDQ36126134-5DD1680E-D7DB-449F-A7D1-11FF43693E7CQ36508959-EEE0BD27-DFD0-4AB8-8B70-A7161196888BQ37652882-757646A9-6E7B-4237-8FC6-E86CE9B35C65Q37792821-FAC81CA8-2B30-47E3-ADAA-03DD76D47D9CQ37914108-ECB3BB7A-739D-4505-9A97-007E52B3469AQ38299946-90D97851-0099-4E5E-A17A-40837D609DEBQ38894418-E9F287DC-18D2-4A2A-9466-0D9D77AD77E4Q39440364-65B18E16-5F6A-4FDF-BBAF-C8BB8BC18DB0Q39939254-06723F79-4EF3-4FCD-852F-B6DD8BE20FE7Q40239182-4AB40F6E-5FF2-4144-8FF3-6A256344F816Q41597239-E9FC41D4-B9C0-4703-890E-7CA15AA73D49Q41725789-186E64BF-26BF-4127-85C2-C57694F5D118Q42499566-4E03E059-88B2-4F55-B032-EE3830C35A1AQ46255293-7F86A95C-88F4-438B-996D-B32751CF2DD8Q47177541-FA605CD8-43DD-4C76-B91C-CFC70F1CE596Q50963043-08239510-561E-45D7-80B9-07537995C675Q52552043-5F77A773-A87D-415A-BEAC-87156BD2087DQ55021792-ABDD7C72-0BD7-4445-87EF-BC9B6366BCE8Q57502479-9C6A4FE9-1FA9-461A-A1CC-94C35AC0F7A7Q58482136-4CE5DD22-F5C3-4299-A314-F7FCDFDF09B7
P2860
Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
Therapy-related acute myeloid ...... otoxins: estimating the risks.
@en
type
label
Therapy-related acute myeloid ...... otoxins: estimating the risks.
@en
prefLabel
Therapy-related acute myeloid ...... otoxins: estimating the risks.
@en
P2093
P2860
P356
P1476
Therapy-related acute myeloid ...... otoxins: estimating the risks.
@en
P2093
Rubinstein L
Ungerleider RS
P2860
P356
10.1002/MPO.2950230205
P577
1994-01-01T00:00:00Z